Santaris inks RNA development pact with Shire

Denmark's Santaris has nailed down a $6.5 million upfront in a new development pact with the UK's Shire. And it will pick up another $13.5 million in near-term milestones as it wraps up early studies. The pact packages five drug programs using Santaris' LNA technology that inhibits segments of RNA that play a role in rare genetic diseases. Santaris stands to gain $72 million in milestones for each of the five drug programs. Release | Report

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.